◀ Back to GP9

FGB — GP9

Text-mined interactions from Literome

Lipscomb et al., J Lab Clin Med 1999 : The platelet glycoprotein complex alphaIIb beta3 is required for platelet-fibrinogen binding and platelet aggregation
Boughalem et al., Ann Cardiol Angeiol (Paris) 2001 (Angina, Unstable) : Platelet glycoprotein IIb/IIIa inhibitors block fibrinogen binding to platelets, and the effect of this on the final common pathway of platelet aggregation makes these compounds extremely potent antiplatelet drugs
Richardson et al., Drug Metab Dispos 2006 (Enterobacteriaceae Infections) : Hepatic alpha1-acid glycoprotein was induced in both groups, whereas alpha-fibrinogen and angiotensinogen were unchanged
Said et al., Clin Res Cardiol 2007 (Acute Disease...) : Thrombocyte glycoprotein IIb/IIIa inhibitors prevent fibrinogen binding and thereby thrombocyte aggregation
DiMinno et al., Blood 1985 (Diabetes Mellitus, Type 1) : The combined data suggest that the glycoprotein IIb-IIIa complex of platelets from diabetic subjects is similar to that of platelets from normal subjects and that the increased fibrinogen binding and aggregation of platelets from diabetic subjects in response to ADP or collagen is mediated by increased formation of prostaglandin endoperoxide or thromboxane A2, or both